Sunshine and rash: Testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash

Aminah Jatoi

doi:10.3816/SCT.2007.n.015

Sunshine and rash: Testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash

Aminah Jatoi

Medical Oncology

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Most patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash. To date, no effective palliative therapy has been developed for these rashes. This review describes the rationale behind N05C4, a placebo-controlled trial of sunscreen as an intervention to prevent EGFR inhibitor-related rash.

Original language	English (US)
Pages (from-to)	198-202
Number of pages	5
Journal	Supportive Cancer Therapy
Volume	4
Issue number	4
DOIs	https://doi.org/10.3816/SCT.2007.n.015
State	Published - Sep 2007

Keywords

Prevention
Squamous cell carcinoma
Ultraviolet light

ASJC Scopus subject areas

Oncology
Pharmacology
Cancer Research

Access to Document

10.3816/SCT.2007.n.015

Cite this

@article{ea459c7f93574d69a356f5c24b3e21b4,

title = "Sunshine and rash: Testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash",

abstract = "Most patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash. To date, no effective palliative therapy has been developed for these rashes. This review describes the rationale behind N05C4, a placebo-controlled trial of sunscreen as an intervention to prevent EGFR inhibitor-related rash.",

keywords = "Prevention, Squamous cell carcinoma, Ultraviolet light",

author = "Aminah Jatoi",

year = "2007",

month = sep,

doi = "10.3816/SCT.2007.n.015",

language = "English (US)",

volume = "4",

pages = "198--202",

journal = "Supportive Cancer Therapy",

issn = "1543-2912",

publisher = "Cancer Information Group, LP",

number = "4",

}

TY - JOUR

T1 - Sunshine and rash

T2 - Testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash

AU - Jatoi, Aminah

PY - 2007/9

Y1 - 2007/9

N2 - Most patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash. To date, no effective palliative therapy has been developed for these rashes. This review describes the rationale behind N05C4, a placebo-controlled trial of sunscreen as an intervention to prevent EGFR inhibitor-related rash.

AB - Most patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash. To date, no effective palliative therapy has been developed for these rashes. This review describes the rationale behind N05C4, a placebo-controlled trial of sunscreen as an intervention to prevent EGFR inhibitor-related rash.

KW - Prevention

KW - Squamous cell carcinoma

KW - Ultraviolet light

UR - http://www.scopus.com/inward/record.url?scp=35348967015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348967015&partnerID=8YFLogxK

U2 - 10.3816/SCT.2007.n.015

DO - 10.3816/SCT.2007.n.015

M3 - Review article

C2 - 18632517

AN - SCOPUS:35348967015

SN - 1543-2912

VL - 4

SP - 198

EP - 202

JO - Supportive Cancer Therapy

JF - Supportive Cancer Therapy

IS - 4

ER -

Sunshine and rash: Testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this